Posted by Michael Wonder on 14 Dec 2020
ExCellThera receives Priority Medicines (PRIME) designation from European Medicines Agency for ECT-001 cell therapy
11 December 2020 - ExCellThera announced today that ECT-001 cell therapy has been granted PRIority MEdicines (PRIME) designation by the EMA for use in urgent allogeneic haematopoietic stem cell transplants.
The ECT-001 technology, comprised of the UM171 small molecule and an optimised culture system, is used in novel curative blood transplant therapies for patients with blood cancers and disorders.
